Latest "Cognitive Function in Adults With Cardiac Disease" News Stories

08:43 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Cognitive Function in Adults With Cardiac Disease" found in our extensive news archives from over 250 global news sources.

More Information about Cognitive Function in Adults With Cardiac Disease on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cognitive Function in Adults With Cardiac Disease for you to read. Along with our medical data and news we also list Cognitive Function in Adults With Cardiac Disease Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cognitive Function in Adults With Cardiac Disease Companies for you to search.

Showing "Cognitive Function Adults With Cardiac Disease" News Articles 1–25 of 19,000+

Thursday 21st March 2019

ZipLine Medical Announces New Emergency Department Study Showing Significant Time and Cost Savings, and Superior Patient Satisfaction, with Laceration Closure Using Zip® Surgical Skin Closure

ZipLine Medical, Inc. today announced presentation of positive results from a randomized, prospective clinical study conducted at the Karolinska University Hospital in Stockholm, Sweden demonstrating both clinical and economic benefits of the Zip® Surgical Skin Closure device when used in an emergency medicine setting for lacerations. A poster...

Teleflex Announces Real-World Data Demonstrating the Effectiveness of the UroLift® System to Treat Patients with Enlarged Prostate

Findings Presented at European Association of Urology Show Consistent Positive Results for Minimally Invasive UroLift System Treatment Teleflex Incorporated (NYSE:TFX) today announced that multiple studies were presented at the 2019 European Association of Urology (EAU) meeting in Barcelona, Spain, highlighting the effectiveness of the UroLift® System...

Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that interim clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in an or...

Antiepileptics increase the risk of #pneumonia in people with Alzheimer’s disease  #Alzheimers #epilepsy

Antiepileptics increase the risk of #pneumonia in people with Alzheimer’s disease  #Alzheimers #epilepsy #pharma

AGH Study Advances Tool Used in Determining Treatment for Patients with Pulmonary Arterial Hypertension

Based on results of a research conducted at Allegheny General Hospital, the REVEAL 2.0 risk score calculator is expected to become the most commonly used risk prognostic tool for patients suffering from pulmonary arterial hypertension. PITTSBURGH, Pa. (PRWEB) March 21, 2019 A study conducted by researchers at Allegheny General Hospital (AGH), part of Allegheny Health Network (AHN), has demonstrat...

Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial

--Study will test efficacy and safety of novel docetaxel-based oral therapeutic-- Modra Pharmaceuticals B.V. (“Modra”) today announced that the first patients have been treated in its Phase IIa study in patients with recurrent or metastatic HER-2 negative breast cancer. The trial will evaluate the efficacy and safety of Modra’s lead product, Modr...

Sherlock Biosciences Launches to Provide Better, Faster and More Affordable Diagnostic Testing Worldwide Through Engineering Biology

CRISPR and Synthetic Biology Platforms SHERLOCKTM and INSPECTRTM Hold Potential to Disrupt Diagnostics Founders include scientific pioneers and diagnostics veterans Omar Abudayyeh, James J. Collins, Rahul K. Dhanda, Todd Golub, Jonathan Gootenberg, Deborah Hung, Pardis Sabeti, David Walt and Feng Zhang Committed ...

AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein, in Children with Genetic Diagnosis of NLRC4-MAS Mutation or XIAP Deficiency, with Amended Design in the U.S.

LAUSANNE, Switzerland, March 21, 2019 / B3C newswire / -- AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced today that a single-arm open label design with a randomized withdrawal phase for its ongoing pivotal Phase 3 trial under an Investigational New Drug (IND) App...

Laser-targeted removal of prostate tumours is as effective as complete prostate removal

A research group led by prostate cancer treatment pioneer Dr Eric Walser, have shown that selectively destroying cancerous prostate tissue is as effective as complete prostate removal or radiation therapy while preserving more sexual and urinary function...

Adrenomed's Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II

DGAP-News: Adrenomed AG / Key word(s): Study/Statement 21.03.2019 / 09:15 The issuer is solely responsible for the content of this announcement. Adrenomed's Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II - AdrenOSS-II trial continues as planned after positive interim efficacy analysis triggered by the treatment of 50% of randomized patients -...

Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer

Three-year follow-up data show comparable overall survival between biosimilar ONTRUZANT® (trastuzumab) and reference medicine HERCEPTIN®i (trastuzumab)ii in early and locally advanced HER2-positive breast cancer Data presented today at the 16th St. Gallen International Breast Cancer Conference 2019 ...

Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis

Sanofi, Lead Pharma’s collaborative partner in the development of SAR441169, successfully initiated first human dosing with this novel RORγt Inverse Agonist candidate treatment For Lead Pharma this represents a fourth payable milestone in the SAR441169 collaboration with Sanofi Lead Pharma, a pharmaceutical compa...

Bavarian Nordic Awards Restricted Stock Units to Executive Management

COPENHAGEN, Denmark, March 21, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management.  The Board of Directors of Bavarian Nordic A/S believes that restricted stock units as an incentive will further increase the long-term shared interests between the Executive Management and t...

Bavarian Nordic Announces Annual Report 2018

COPENHAGEN, Denmark, March 21, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2018. Below is a summary of business progress, financial performance for the year and financial outlook for 2019 from the report. The full report is attached as a PDF file and can be found on the company's website,  Delivering on ...

Biogen scraps Alzheimer's trial, shares skid

Biogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for an industry keen to develop treatments for the memory-robbing disease.

Biogen, Eisai scrap Alzheimer drug trials

Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.

Probiodrug AG: Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019

DGAP-News: Probiodrug AG / Key word(s): Miscellaneous 21.03.2019 / 07:00 The issuer is solely responsible for the content of this announcement. Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019 HALLE (SAALE), Germany, 21 March 2019 - Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Al...

Gelesis Announces Three Presentations at Annual Endocrine Society Meeting

Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced the Company will deliver three poster presentations at ENDO, the Endocrine Society Annual Meeting, held in New Orleans from March 23-26. Two of the presentations will...

Daily briefing: How a ‘super-smeller’ can sniff out Parkinson’s disease

Tianjin's CanSino to Raise $160.5 Million for Novel Vaccines in Hong Kong IPO

Tianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas. Its Ebola vaccine has been approved for use, and the company's meningitis and a meningococcal vaccines are near-NDA stage. Both candidates have demonstrated superior safety profiles and im...

Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function

Isolated seniors chat online to prevent cognitive decline

Right now, Gene Gilmer is as sharp as ever at 90 years of age. A retired school superintendent who earned his doctorate in math decades ago, Gilmer lives alone and worries about losing the memories that defined his life.

Wednesday 20th March 2019

Epigenetics and epigenomics in diabetic kidney disease and metabolic memory

Bacterial cell wall offcasts linked to autoimmune disease

New mobile DNA element in Wolbachia may contribute to improved disease control strategies

Controlling mosquito-borne illnesses, such as Dengue or West Nile virus, has historically been difficult due to a lack of effective vaccines and concerns about the environmental impact of insecticides.

Quick Search


News Quicklinks